» Articles » PMID: 36473077

Gestational Glucose Intolerance and Risk of Future Diabetes

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2022 Dec 6
PMID 36473077
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Pregnant individuals are universally screened for gestational diabetes mellitus (GDM). Gestational glucose intolerance (GGI) (an abnormal initial GDM screening test without a GDM diagnosis) is not a recognized diabetes risk factor. We tested for an association between GGI and diabetes after pregnancy.

Research Design And Methods: We conducted a retrospective cohort study of individuals followed for prenatal and primary care. We defined GGI as an abnormal screening glucose-loading test result at ≥24 weeks' gestation with an oral glucose tolerance test (OGTT) that did not meet GDM criteria. The primary outcome was incident diabetes. We used Cox proportional hazards models with time-varying exposures and covariates to compare incident diabetes risk in individuals with GGI and normal glucose tolerance.

Results: Among 16,836 individuals, there were 20,359 pregnancies with normal glucose tolerance, 2,943 with GGI, and 909 with GDM. Over a median of 8.4 years of follow-up, 428 individuals developed diabetes. Individuals with GGI had increased diabetes risk compared to those with normal glucose tolerance in pregnancy (adjusted hazard ratio [aHR] 2.01 [95% CI 1.54-2.62], P < 0.001). Diabetes risk increased with the number of abnormal OGTT values (zero, aHR 1.54 [1.09-2.16], P = 0.01; one, aHR 2.97 [2.07-4.27], P < 0.001; GDM, aHR 8.26 [6.49-10.51], P < 0.001 for each compared with normal glucose tolerance). The fraction of cases of diabetes 10 years after delivery attributable to GGI and GDM was 8.5% and 28.1%, respectively.

Conclusions: GGI confers an increased risk of future diabetes. Routinely available clinical data identify an unrecognized group who may benefit from enhanced diabetes screening and prevention.

Citing Articles

The interdependence of mid-trimester blood pressure and glucose levels in shaping fetal growth and neonatal outcomes: implications for risk-benefit assessment and co-management.

Lv L, Yang J, Li L, Huang C, Shi H, Fang Y BMC Med. 2025; 23(1):161.

PMID: 40087732 DOI: 10.1186/s12916-025-03990-7.


Hematologic dynamics during pregnancy and their association with obstetric complications: a retrospective cohort study.

Tozzo V, Petherbridge R, James K, Hsu S, Michalopoulos C, Foy B medRxiv. 2025; .

PMID: 39990572 PMC: 11844592. DOI: 10.1101/2025.02.13.25322250.


Association of maternal blood metabolomics and gestational diabetes mellitus risk: a systematic review and meta-analysis.

Zhou J, Yu J, Ren J, Ren Y, Zeng Y, Wu Y Rev Endocr Metab Disord. 2024; .

PMID: 39602052 DOI: 10.1007/s11154-024-09934-5.


Are miR-26a and miR-26b microRNAs potent prognostic markers of gestational diabetes?.

Ghaneialvar H, Mehrab Mohseni M, Kenarkoohi A, Kakaee S Health Sci Rep. 2024; 7(6):e2152.

PMID: 38831779 PMC: 11144624. DOI: 10.1002/hsr2.2152.


Risk of Neonatal Hypoglycemia in Infants of Mothers With Gestational Glucose Intolerance.

Andrews C, Maya J, Schulte C, Hsu S, Thaweethai T, James K Diabetes Care. 2024; 47(7):1194-1201.

PMID: 38787410 PMC: 11208751. DOI: 10.2337/dc23-2239.


References
1.
Retnakaran R, Qi Y, Sermer M, Connelly P, Hanley A, Zinman B . Glucose intolerance in pregnancy and future risk of pre-diabetes or diabetes. Diabetes Care. 2008; 31(10):2026-31. PMC: 2551649. DOI: 10.2337/dc08-0972. View

2.
Berezowsky A, Raban O, Aviram A, Zafrir-Danieli H, Krispin E, Hadar E . Glucose tolerance test with a single abnormal value in pregnancy and the risk of type-2 diabetes mellitus. Arch Gynecol Obstet. 2021; 305(4):869-875. DOI: 10.1007/s00404-021-06207-3. View

3.
Kim C, Newton K, Knopp R . Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002; 25(10):1862-8. DOI: 10.2337/diacare.25.10.1862. View

4.
Leong A, Berkowitz S, Triant V, Porneala B, He W, Atlas S . Hypoglycemia in Diabetes Mellitus as a Coronary Artery Disease Risk Factor in Patients at Elevated Vascular Risk. J Clin Endocrinol Metab. 2015; 101(2):659-68. PMC: 4880119. DOI: 10.1210/jc.2015-3169. View

5.
Lasko T, Atlas S, Barry M, Chueh H . Automated identification of a physician's primary patients. J Am Med Inform Assoc. 2005; 13(1):74-9. PMC: 1380200. DOI: 10.1197/jamia.M1876. View